Literature DB >> 24269940

Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.

Yan Yang1, Yuzhen Tong2, Meng Gong3, Yanrong Lu4, Chengshi Wang4, Mingliang Zhou3, Qiu Yang1, Tingrui Mao1, Nanwei Tong5.   

Abstract

We previously showed that activated peroxisome proliferator-activated receptor (PPAR)β/δ can protect pancreatic β cells against lipotoxic apoptosis. However, the molecular mechanism remained unclear. Glucagon-like peptide-1 receptor (GLP-1R) has been reported to exhibit a protective effect against lipotoxic apoptosis in pancreatic β cells. In the present study, we aimed to investigate the underlying molecular mechanisms that PPARβ/δ activation suppressed apoptosis and improved β cell function impaired by fatty acids, focusing on contribution of GLP-1R. Isolated rat islets and rat insulin-secreting INS-1 cells were treated with the PPARβ/δ agonist GW501516 (GW) in the presence or absence of palmitate (PA) and transfected with siRNA for PPARβ/δ or treated with the PPARβ/δ antagonist GSK0660. Apoptosis was assessed by DNA fragmentation, Hoechst 33342 staining and flow cytometry. GLP-1R expression in INS-1 cells and islets was assayed by immunoblotting, quantitative PCR (qPCR) and immunofluorescence staining. SREBP-1c, Caveolin-1, Akt, Bcl-2, Bcl-xl and caspase-3 expression was measured using immunoblotting and qPCR. Our results showed that PPARβ/δ activation decreased apoptosis in β cells and robustly stimulated GLP-1R expression under lipotoxic conditions. GW enhanced glucose-stimulated insulin secretion (GSIS) impaired by PA through stimulation of GLP-1R expression in β cells. Moreover, SREBP-1c/Caveolin-1 signaling was involved in PPARβ/δ-regulated GLP-1R expression. Finally, GW exerted anti-apoptotic effects via interfering with GLP-1R-dependent Akt/Bcl-2 and Bcl-xl/caspase-3 signaling pathways. Our study suggested that the anti-apoptotic action of GW may involve its transcriptional regulation of GLP-1R, and PPARβ/δ activation may represent a new therapeutic method for protecting pancreatic β cells from lipotoxicity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; ELISA; Ex; FBS; FDA; FFA; FITC; G protein coupled receptor; GLP-1R; GPCR; GSIS; GW; GW501516; HBSS; Hanks' balanced salt solution; KRBH; PA; PI; PPARβ/δ; Palmitate; Pancreatic β cells; SREBP-1c; T2D; enzyme-linked immunosorbent assay; exendin-4; fetal bovine serum; fluorescein diacetate; fluorescein isothiocyanate; free fatty acid; glucagon-like peptide-1 receptor; glucose-free Krebs–Ringer bicarbonate HEPES buffer; glucose-stimulated insulin secretion; palmitate; peroxisome proliferator-activated receptor β/δ; propidium iodide; qPCR; quantitative polymerase chain reaction; sterol regulatory element binding protein-1c; type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 24269940     DOI: 10.1016/j.cellsig.2013.11.019

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  15 in total

1.  Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.

Authors:  Adeline Péchery; Sylvie Fauconnet; Hugues Bittard; Isabelle Lascombe
Journal:  Tumour Biol       Date:  2016-09-16

2.  Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.

Authors:  Chenghu Huang; Li Yuan; Shuyi Cao
Journal:  Int J Mol Med       Date:  2015-05-12       Impact factor: 4.101

3.  Long- but not short-term adult-onset, isolated GH deficiency in male mice leads to deterioration of β-cell function, which cannot be accounted for by changes in β-cell mass.

Authors:  Jose Cordoba-Chacon; Manuel D Gahete; Naveen K Pokala; David Geldermann; Maria Alba; Roberto Salvatori; Raul M Luque; Rhonda D Kineman
Journal:  Endocrinology       Date:  2013-12-16       Impact factor: 4.736

4.  HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.

Authors:  Yueming Chen; Qiang Ren; Zongtao Zhou; Liming Deng; Lijun Hu; Luyong Zhang; Zheng Li
Journal:  Br J Pharmacol       Date:  2020-02-08       Impact factor: 8.739

5.  Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages.

Authors:  C Guo; T Huang; A Chen; X Chen; L Wang; F Shen; X Gu
Journal:  Braz J Med Biol Res       Date:  2016-11-21       Impact factor: 2.590

6.  Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.

Authors:  Jing Ke; Ye Liu; Jin Yang; Ran Lu; Qing Tian; Wenfang Hou; Guang Wang; Rui Wei; Tianpei Hong
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

7.  Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.

Authors:  Jui-Ting Chang; Yao-Jen Liang; Chia-Yu Hsu; Chao-Yi Chen; Po-Jung Chen; Yi-Feng Yang; Yen-Lin Chen; Dee Pei; Jin-Biou Chang; Jyh-Gang Leu
Journal:  BMC Pharmacol Toxicol       Date:  2017-10-24       Impact factor: 2.483

8.  Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.

Authors:  Yasuo M Tsutsumi; Rie Tsutsumi; Eisuke Hamaguchi; Yoko Sakai; Asuka Kasai; Yoshihiro Ishikawa; Utako Yokoyama; Katsuya Tanaka
Journal:  Cardiovasc Diabetol       Date:  2014-09-07       Impact factor: 9.951

9.  Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.

Authors:  Yoshifumi Ashikawa; Yuhei Nishimura; Shiko Okabe; Shota Sasagawa; Soichiro Murakami; Mizuki Yuge; Koki Kawaguchi; Reiko Kawase; Toshio Tanaka
Journal:  Front Pharmacol       Date:  2016-07-11       Impact factor: 5.810

Review 10.  PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders.

Authors:  Xavier Palomer; Emma Barroso; Javier Pizarro-Delgado; Lucía Peña; Gaia Botteri; Mohammad Zarei; David Aguilar; Marta Montori-Grau; Manuel Vázquez-Carrera
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.